On October 16, 2014, the fee-for-service (FFS) pharmacy program implemented clinical criteria for Hepatitis C Virus (HCV) drug therapy, as was recommended by the Drug Utilization Review Board (DURB) at the September 18, 2014 meeting. Included in this criteria were the following ...
- NY Governor Announces Nation’s First State-Level Hep C Elimination Strategy March 16, 2018
- NYC Council Viral Hepatitis Initiative March 9, 2018
- Sign On | Urge Congress to Appropriate Opioid Funding for Hep C/ HIV February 14, 2018
- Training Manual for Treatment Activists | Hep C & HIV Coinfection February 2, 2018
May 1 - May 31